Tirzepatide, a GLP1R and GIP receptor (GIPR) dual agonist, reduced NASH biomarkers like ALT and AST in a phase II trial (NCT03131687) [154], with further studies ongoing (NCT04166773). Here, GIPR is linked to metabolic dysfunction-associated steatohepatitis.